A receptor tyrosine kinase ROR1 inhibitor (KAN0439834) induced significant apoptosis of pancreatic cells which was enhanced by erlotinib and ibrutinib

Amir Hossein Daneshmanesh1,2, Mohammad Hojjat-Farsangi1,2, Amineh Ghaderi1,2, Ali Moshfegh1,2, Lotta Hansson1,2,3, Johan Schultz4, Jan Vågberg4, Styrbjörn Byström4, Elisabeth Olsson4, Thomas Olin4, Anders Österborg1,2,3, Håkan Mellstedt1,2,3*

1 Department of Oncology-Pathology, Immune and Gene therapy Lab, Cancer Center Karolinska (CCK), Karolinska University Hospital Solna, Stockholm, Sweden, 2 Karolinska Institutet, Stockholm, Sweden, 3 Department of Hematology, Karolinska University Hospital Solna, Stockholm, Sweden, 4 Kancera AB, Karolinska Institutet Science Park, Stockholm, Sweden

* hakan.mellstedt@slu.se

Abstract

There is a great unmet medical need in pancreatic carcinoma (PC) for novel drugs with other mechanisms of action than existing. PC cells express the onco-fetal RTK ROR1, absent on most normal post-partem cells. ROR1 is involved in proliferation, survival, EMT and metastasis of tumor cells in various malignancies. A small molecule inhibitor (KAN0439834) (530 Da) targeting the TK domain of ROR1 was developed and the activity in ROR1 expressing human PC cell lines (n = 8) evaluated. The effects were compared to a murine mAb against the external part of ROR1, gemcitabine, erlotinib and ibrutinib. KAN0439834 induced significant apoptosis of the tumor cells. EC50 values for KAN0439834 varied between 250–650 nM depending on the cell line. The corresponding values for erlotinib and ibrutinib were 10–40 folds higher. KAN0439834 was much more effective in inducing tumor cell death than the ROR1 mAb although both inhibited ROR1 phosphorylation and downstream non-canonical Wnt pathway molecules. Combination of KAN0439834 with erlotinib or ibrutinib had significant additive effects on tumor cell death. A first-in-class small molecule ROR1 inhibitor (KAN0439834) showed promising in vitro activity against a number of human PC cell lines. Interesting is the additive effects of erlotinib and ibrutinib which warrants further studies as both these agents are in clinical trials for pancreatic carcinoma.

Introduction

Pancreatic cancer is one of the most aggressive human malignancies and the fourth leading cause of cancer-related death in Europe and the United States [1, 2]. More than 50% of patients with pancreatic cancer are diagnosed with metastases. In 30–40% of patients the disease is localized but surgically not resectable. Even patients with a resectable tumor have a poor outcome. The median survival after surgery including adjuvant therapy is only 2 years [3].
Gemcitabine was for a long time standard first-line treatment of patients with unresectable or metastatic pancreatic cancer. Gemcitabine is still used in adjuvant therapy, while combination regimens for metastatic disease have become the standard – 5-fluorouracil (5-FU)/leucovorin with irinotecan and oxaliplatin (FOLFIROAD) or nab-paclitaxel with gemcitabine are the most widely used. With these approaches, a progression-free survival (PFS) of 23–31% at 6–7 months has been noted, and a median overall survival (OS) between 8 and 11 months. Thus, there is a great need for innovative medicinal treatments [4].

Receptor tyrosine kinases (RTKs) and associated signaling pathways have important functions in regulating the growth of malignant as well as normal cells. Dysregulation contributes to the growth of malignant cells, self-sufficiency, evasion from apoptosis, unlimited cell replication and metastatic capability [5]. Erlotinib, a tyrosine kinase inhibitor (TKI) of the epidermal growth factor receptor (EGFR), is the only RTK targeting agent, which has been approved for treatment of advanced pancreatic cancer but with minor clinical effect [4]. Ibrutinib, a BTK inhibitor, with off-target effects including EGFR [6] is in phase II-III clinical trials for advanced pancreatic carcinoma (www.clinicaltrials.gov).

ROR1 is a transmembrane protein belonging to the ROR family and one of the twenty RTK families [7], consisting of 937 amino acid residues with extra- and intracellular domains. The extracellular part includes 3 regions: the Ig-like, the cysteine rich (CRD) and the kringle (KNG) domains. The CRD and KNG domains are the ligand binding sites. The intracellular part of ROR1 contains a tyrosine kinase domain, which can be triggered by other intracytoplasmic signaling proteins.

ROR1 is highly expressed during embryogenesis of the central nervous system as well as in the heart, skeletal muscle and pulmonary systems. Adult normal tissues with the exception of adipose tissue, a small early B-cell subset and cells of the upper gastrointestinal tract do not express ROR1 [8]. ROR1 is a highly conserved member of orphan receptors among species and involved in a variety of signaling pathways governing cell growth and epithelial-mesenchymal transition [9]. One of the ligands for ROR1 is Wnt5a [10]. ROR1 has been suggested to be a survival factor for various malignancies including chronic lymphocytic leukemia (CLL), breast cancer, lung adenocarcinoma, ovarian carcinoma, pancreatic carcinoma and glioblastoma [11]. ROR1 seems to play an important role in cell signaling of significance for tumorigenesis as the PI3K/AKT/mTOR pathway and EGFR mediated signaling [9]. Anti-ROR1 monoclonal antibodies (mAbs) and ROR1 specific RNA interference (RNAi) molecules induced apoptosis and growth impairment of several types of malignant cells expressing ROR1 including pancreatic carcinoma [12–14].

In the present study, we analyzed the apoptotic effects of a first-in-class ROR1 small molecule, KAN0439834, targeting the TK domain of ROR1, in a panel of human pancreatic cancer cell lines. The effect of KAN0439834 was compared to gemcitabine, erlotinib, ibrutinib and a murine ROR1 mAb.

Materials and methods

Cell lines

The pancreatic cancer cell lines AsPC-1 (ECACC nr. 96020930), BxPC-3 (ECACC nr. 93120816), CFPAC-1 (ATCC nr. CRL-1918), PaCa-2 (ATCC nr. CRL-1420), Capan-2 (ATCC nr. HTB-80), Capan-1(ATCC nr. HTB-79) and HPAF-II (ATCC nr. CRL-1997) (S1 Table) were obtained from European Collection of Authenticated Cell Cultures (ECACC, Porton Down, Salisbury, UK) and American Type Culture Collection (ATCC, Rockville, MD, USA). The pancreatic cell line PaCa-44 was a kind gift from Dr. Matthias Löh (Karolinska University Hospital Huddinge, Stockholm, Sweden). Capan-1, Capan-2, PaCa-44 and BxPC-3 cells were
cultured in DMEM/F12 medium (Gibco, Life Technologies, Karlsruhe, Germany). PaCa-2 cells were cultured in DMEM (high glucose) medium (Gibco) and AsPC-1, CFPAC-1 and HPAF-II cells were cultured in RPMI medium (Gibco) containing 10% FCS (Gibco), 2% glutamine (Biochrom KG, Berlin, Germany) and 100 ug/ml penicillin/ streptomycin (Biochrom KG) at 37˚C in a humidified incubator with 5% CO2.

**Enrichment of the ROR1**

Surface ROR1**+** and ROR1**−** fractions respectively from the crude PaCa-2 pancreatic cancer cell line (about 60% surface ROR1**+** cells) were separated by cell sorting using ROR1-APC conjugated antibody (Miltenyi Biotec, Bergisch Gladbach, Germany). FACSAria II Cell Sorter (BD Biosciences, San Jose, CA, USA) was used. The surface ROR1**+** fraction showed >95% positive cells and in the ROR1 negative fraction <5% ROR1**+** cells were found (flow-cytometry).

**Anti-ROR1 monoclonal antibodies**

Mouse mAbs against ROR1 were generated against the extracellular CRD domain of ROR1 as previously described [15]. One mAb, anti-ROR1 CRD 1D8 (IgG1) was selected for the current study.

**KAN0439834 a small molecule directed against the TK domain of ROR1**

KAN0439834 is an oral available small molecule (535 Da) type I tyrosine kinase inhibitor (TKI) targeting the intracellular ROR1 TK domain inhibiting phosphorylation of tyrosine residues 641 and 646. For further details see ref. [16].

**Flow cytometric analysis**

Cell surface staining was performed as previously described [15]. Briefly, 10^6 cells were washed in PBS and suspended in 100 μl of FACS buffer (PBS, 0.1% sodium azide, and 0.5% BSA) and PE conjugated anti-ROR1 (Miltenyi Biotec, Bergisch Gladbach, Germany) mAb and incubated for 20 min at room temperature (RT). Cells were washed with FACS buffer and fixed with 1% paraformaldehyde in PBS. A FACS Canto II flow cytometry (BD Biosciences, San Jose, CA, USA) was used to analyze the frequency of ROR1 expressing cells. 5x10^4 events were collected and cells were analyzed using the FlowJo software program (Tree Star Inc. Ashland, OR, USA).

**Western blot analysis**

10x10^6 cells were lysed in 200 μl of lysis buffer [0.1% SDS, 1% Triton X-100, 50 mM Tris- HCl, pH 7.4, 150 mM NaCl, 5 mM EDTA, with 1% protease inhibitor cocktail (Sigma-Aldrich, Saint Louis, MO, USA) containing phosphatase inhibitor (Roche, Basel, Switzerland) on ice for 30 min and centrifuged at 13000 rpm. Supernatants were collected and protein concentration measured by the BCA Protein Assay Kit (ThermoFisher Scientific, IL, USA). For Western blot experiment, 10 μg of the cell lysate was run on 10% Bis-Tris SDS-PAGE gel at 120V/90mA for 2 h. After electrophoresis, proteins were transferred to PVDF membrane (Millipore Corporation, Bedford, MA, USA) and blocked overnight at 4˚C with 5% BSA in TBS containing 0.1% Tween 20 (TBS-T). Membranes were probed with the respective primary antibodies overnight at 4˚C. After washing four times with TBS-T, the filters were incubated with peroxidase-conjugated secondary rabbit anti-goat or mouse antibodies (Dako) for 1 h at room temperature (RT). Membranes were washed four times and developed with the advanced ECL chemoluminescence detection system (GE Healthcare, Uppsala, Sweden). The following antibodies were used.
to analyze total and phosphorylated (p) proteins; ROR1 (R&D Systems), pROR1 (Tyr 641 and 646, Ser 652), LRP6 and p-LRP6 (Ser 1490), SRC and p-SRC (Tyr 416), PI3K p110δ, AKT and p-AKT (Ser 473), mTOR and p-mTOR (Ser 2448), CREB and p-CREB (Ser 133) (Cell Signaling Technology, Danvers, MA, USA) and p-PI3K p110δ (Santa Cruz Biotechnology, CA, USA).

For the analysis of proteins involved in apoptosis, cleaved poly-(ADP ribose)-polymerase (PARP) and caspase-3 as well as MCL-1 and Bcl-xL were analyzed by Western blot after preparation of cell lysates from the apoptosis experiments (see above). Briefly, 10 μg of protein lysate was run on Western blot gels. Filters were incubated with rabbit anti-PARP, cleaved caspase-3, MCL-1 and Bcl-xL antibodies (Cell Signaling Technology) overnight at 4˚C, and subsequently with a secondary peroxidase-conjugated goat anti-rabbit antibody. Blots were developed with the ECL chemiluminescence detection system [15]. For loading control, membranes were probed for β-actin (Sigma-Aldrich). Densitometric quantification was carried out using the ImageJ software (National Institute of Health, USA). Ratios were calculated between the phosphorylated and the total protein.

**Annexin V/PI apoptosis assay**

A total of 5x10⁴ cells from the pancreatic cancer cell lines and healthy PBMC were incubated in 24 well plates. After 24 h of incubation, medium was replaced and cells incubated with KAN0439834 (500 nM) in DMEM containing 10% FBS and as controls the anti-ROR1 mAb (10 μg/mL) (optimal dose 10–20 μg/mL in apoptosis experiments [15]) and an isotype control mAb (ThermoFisher Scientific). After 24–72 h of incubation at 37˚C cells were collected and washed with PBS and suspended in 100 μl of Annexin V binding buffer (BD Biosciences) containing FITC-conjugated Annexin V and PI (Propidium Iodide) (BD Biosciences) and incubated at RT in the dark for 20 min. After incubation, 150 μl of Annexin V binding buffer was added. Viable cells were identified as the double negative Annexin V/PI population. Apoptosis was determined by flow cytometry (FACS Canto II, BD Biosciences) analyzed by the FlowJo software program (Treestar Inc.).

**Cytotoxicity assay (MTT)**

The MTT [3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide] assay (Sigma-Aldrich) was used to measure cytotoxicity. Briefly, 1x10⁴ pancreatic cancer cells were incubated in triplicates in 200 μl of DMEM containing 10% FBS in 96 well plates with KAN043 9834 as well as anti-ROR1 mAb, an isotype control mAb, gemcitabine (Eli Lilly, IN, USA), erlotinib (Roche) and ibrutinib (AbbVie, IL, USA). Cells were cultured for 24–72 h. 20 μl MTT solution was added and the cell suspension incubated for 4 h at 37˚C. The reaction was stopped by adding MTT solvent (10% SDS in 0.01 M HCL). The plate was read by a microplate reader at 595 nm.

**Human-phospho-RTK array**

Phosphorylation of RTKs in PaCa-2 cells was analyzed by the Proteome Profiler Array Kit (Human-phospho-RTK array) (R&D Systems) according to the manufacturer’s protocol. Briefly, membranes were blocked and incubated with 700 μg of PaCa-2 cells lysate overnight at 4˚C, washed 3 times in washing buffer and incubated with the secondary antibody (HRP-conjugated anti-phosphotyrosine) for 2 h at RT. Membranes were washed 3 times with washing buffer before development with ECL Western blotting detection reagent (GE Healthcare). Spots of different RTKs were visualized using ECL chemiluminescence detection system (GE Healthcare). The levels of phosphorylated RTKs were densitometrically quantified using
ImageJ software (National Institute of Health, USA) and normalized to internal phosphotyrosine-positive controls.

**Proximity ligation assay (PLA)**

PLA assay (Duolink In Situ Red Starter Kit Mouse/Rabbit, Sigma-Aldrich) was performed to determine co-localization of ROR1 and LRP6 in PaCa-2 cells. Briefly, untreated and KAN0439834 treated (4 h) PaCa-2 cells were cultured on 8 chamber polystyrene culture slides (Falcon, NY, USA) overnight. Slides were washed twice with PBS and fixed with 4% paraformaldehyde for 20 min and then blocked for 1 h at RT, using blocking buffer. Then, the cells were incubated with mouse anti-human ROR1 (Sigma-Aldrich) and rabbit anti-human LRP6 (Cell Signaling Technology) for overnight at +4°C. After washing, cells were incubated with Plus and Minus oligos for 1 h at 37°C, followed by ligation and amplification processes for 30 and 100 min, respectively. PLA-signals (red fluorescent spots), each representing a close proximity of these two targets, were examined by Olympus fluorescent microscope and data were captured by an Olympus DP21 camera. The signal obtained by primary irrelevant Abs from mouse and rabbit were used as negative control.

**Statistics**

Statistical analyses were done using Student’s t-test and Mann-Whitney U test as appropriate by the GraphPad Prism software (GraphPad Software, Inc., La Jolla, CA, USA). IC50 values were obtained by non-linear curve fitting to the Hills equation using GraphPad Prism of the Accord HTS software (Accelrys Inc., San Diego, CA, USA). P-values < 0.05 were considered significant.

**Results**

**ROR1 expression and phosphorylation**

Characteristics of the human pancreatic cancer cell lines are shown in S1 Table. All eight cell lines expressed the ROR1 protein as determined by Western blot (Fig 1A) and flow cytometry (Fig 1B). The frequency of surface ROR1^+^ cells varied from 71% (AsPC-1) to 40% (Capan-1). The cell lines expressed phosphorylated ROR1 (pROR1) – a 130 kDa band representing the fully glycosylated ROR1 (Fig 1C). The PaCa-2 cell line was sorted into surface ROR1^+^ and ROR1^-^ fractions respectively. Both these fractions expressed the phosphorylated ROR1 protein (WB) irrespective of whether ROR1 could be detected on the surface or not (Fig 1D and 1E).

**KAN0439834 induced significantly higher rate of apoptosis than anti-ROR1 mAbs**

Apoptosis (Annexin V/PI) of the pancreatic cancer cell lines induced by KAN0439834 (500 nM) and the control anti-ROR1 mAb (10 μg/ml) were analyzed. First, a time-kinetics (24–72 h) study was performed using the PaCa-2 cell line. Induction of apoptosis by KAN0439834 was significantly higher than the anti-ROR1 mAb at all time points (p<0.001) (S1 Fig). The optimal time point was 72 h of incubation and used in subsequent experiments. KAN0439834 induced a significantly (p<0.05 – <0.001) higher rate of apoptosis than the anti-ROR1 mAb in all pancreatic cancer cell lines (Fig 2A). PaCa-2 was the most sensitive cell line to KAN0439834 in inducing apoptosis (82%) compared to the anti-ROR1 mAb (35%) (p<0.001). Capan-1 was the most resistant cell line to apoptosis to KAN0439834 (20%) but still more effective than the anti-ROR1 mAb (5%) (p<0.01). KAN0439834 was tested for induction of apoptosis in normal PBMC (B and T cells). No significant killing was observed [16].
Using cell lysates of the PaCa-2 cell line from the 24 h of culture (Fig 2A), it could be shown that KAN0439834 and anti-ROR1 mAb induced both PARP and caspase-3 cleavage as well as downregulation of the MCL-1 and Bcl-xL proteins (Fig 2B and 2C) confirming induction of apoptosis by both compounds.

Cytotoxicity of KAN0439834 and anti-ROR1 mAb in ROR1 surface positive and negative subpopulations of the PaCa-2 cell line

Surface ROR1+ and ROR1− fractions of the PaCa-2 cells were obtained by cell sorting. A dose-dependent cytotoxicity (MTT) of the ROR1+ PaCa-2 fraction was observed with the ROR1− fraction...
mAb whereas no killing of the surface negative fraction was observed (Fig 3A). KAN0439834 was equally effective in both surface ROR1⁺ and surface ROR1⁻ subpopulations (Fig 3B). A statistically significant correlation was noted between the frequency of surface ROR1⁺ PaCa-2 fraction and cytotoxicity induced by the anti-ROR1 mAb (p < 0.002) (data not shown). No such correlation existed between the frequency of surface ROR1⁺ PaCa-2 fraction and KAN0439834 induced cytotoxicity (data not shown). The data support the notion of expression of ROR1 without a detectable external domain in tumor cells. Similar relations have also been show for EGFR in lung cancer [17].

Cytotoxicity of KAN0439834, anti-ROR1 mAb, gemcitabine, erlotinib and ibrutinib

There was a close correlation between apoptosis (Annexin V/PI) and cytotoxicity (MTT) in all pancreatic cell lines treated with KAN0439834 in vitro (r = 0.9182; p < 0.0001; n = 25) (S2 Fig).

Cytotoxicity (MTT) of KAN0439834, anti-ROR1 mAb, gemcitabine, erlotinib and ibrutinib alone and in combinations were compared. KAN0439834 in combination with gemcitabine
induced a statistically significant higher cytotoxicity in PaCa-2 cells than KAN0439834 alone (p = 0.0033) but the difference (88% vs 80%) was small (Fig 4A). Adding the ROR1 mAb to KAN0439834 did not augment cytotoxicity (ns). Similar results were obtained with the Capan-1 cell line with the exception that combining KAN0439834 and the anti-ROR1 mAb increased the efficacy compared to KAN0439834 alone (p = 0.0039) (Fig 4B). In BxPC-3 cells, the addition of ROR1 mAb, but not gemcitabine, enhanced cytotoxicity of KAN0439834 (p<0.003 and p = 0.14, respectively) (Fig 4C). The highest additive cytotoxic effect was observed in AsPC-1 cells, both when gemcitabine (p = 0.001) or the ROR1 mAb (p = 0.007) was added to KAN0439834 (Fig 4D). Information on the four other cell lines (CFPAC-1, Capan-2, PaCa-44 and HPAF-II) using KAN0439834 and gemcitabine are presented in S3A–S3D Fig. Data were similar to those described above.

Cytotoxic effects of KAN0439834 and erlotinib alone and in combination was studied in PaCa-2, BxPC-3 and Capan-1 pancreatic cancer cell lines (Fig 5A–5C). EC50 values were 10–20 times higher for erlotinib as compared to KAN0439834 (Table 1). Combination of KAN0439834 and erlotinib showed significant additive effects in all three cell lines compared to either drug alone. Similarly, KAN0439834 and ibrutinib were compared in three cell lines. EC50 values for ibrutinib was 20–40 times higher as compared to KAN0439834 (Table 1). The combination of these two drugs showed significant additive effects (Fig 6A–6C).

**KAN0439834 inhibited phosphorylation of ROR1**

KAN0439834 induced a dose-dependent inhibition of ROR1 phosphorylation which could be detected at 50 nM and was complete at 1000 nM (IC50 for inhibition of ROR1 phosphorylation was <100 nM) (Fig 7A). In contrast, at the optimal cytotoxic dose of the anti-ROR1 mAb (10 µg/mL) only a 50% decrease in phosphorylation of ROR1 was noted (Fig 7B). Inhibition of ROR1 phosphorylation by KAN0439834 was confirmed by a human-phospho-RTK array using percolated nitrocellulose membranes containing 48 different human-phospho-RTKs (Fig 7C and 7D). The assay also showed that KAN0439834 did not dephosphorylate EGFR and IGF-1R, kinases which are overexpressed in pancreatic carcinoma cells [18, 19]. Gemcitabine, erlotinib and ibrutinib did not dephosphorylate ROR1 (data not shown).
Effects of KAN0439834 on ROR1 associated signaling molecules

PaCa-2 cells were incubated with KAN0439834 or anti-ROR1 mAb and molecules associated with ROR1 signaling were analyzed (Fig 8A and 8B). Both KAN0439834 and anti-ROR1 mAb dephosphorylated LRP6 (a co-receptor for ROR1), SRC, PI3K, AKT, mTOR as well as the transcription factor CREB.

Fig 4. Cytotoxicity (MTT) (mean±SEM) of KAN0439834, gemcitabine and anti-ROR1 mAb in pancreatic cancer cell lines. (A) KAN0439834 in PaCa-2 cell line was significantly more effective compared to gemcitabine (p = 0.0001). KAN0439834 and gemcitabine in combination induced significantly higher cytotoxicity compared to KAN0439834 or gemcitabine alone (KAN0439834 plus gemcitabine vs KAN0439834, p = 0.0033, KAN0439834 plus gemcitabine vs gemcitabine, p = 0.0001). No statistically significant difference comparing KAN0439834 with KAN0439834 plus anti-ROR1 mAb. (B) Cytotoxicity of Capan-1 cells (KAN0439834 vs gemcitabine, p = 0.0483, KAN0439834 plus gemcitabine vs KAN0439834, p = 0.0029, KAN0439834 plus gemcitabine vs gemcitabine, p = 0.0009, KAN0439834 plus anti-ROR1 CRD mAb vs KAN0439834, p = 0.0039, KAN0439834 plus anti-ROR1 mAb vs anti-ROR1 mAb, p = 0.0001). (C) Cytotoxicity of BxPC-3 cells (KAN0439834 vs gemcitabine, p = 0.0044, KAN0439834 plus gemcitabine vs KAN0439834, p = 0.1481, KAN0439834 plus gemcitabine vs gemcitabine, p = 0.0111, KAN0439834 plus anti-ROR1 mAb vs KAN0439834, p = 0.0034, KAN0439834 plus anti-ROR1 mAb vs anti-ROR1 mAb, p = 0.0001). (D) Cytotoxicity of AsPC-1 cells (KAN0439834 vs gemcitabine, p = 0.0106, KAN0439834 plus gemcitabine vs KAN0439834, p = 0.0010, KAN0439834 plus anti-ROR1 mAb vs KAN0439834, p = 0.0007, KAN0439834 plus anti-ROR1 mAb vs anti-ROR1 mAb, p = 0.0001).

https://doi.org/10.1371/journal.pone.0198038.g004
ROR1/LRP6 heterodimerization and effects of KAN0439834

ROR1 and the co-receptor LRP6 were physically bound to each other (heterodimerized) on PaCa-2 cells (PLA assay). No dissociation was seen after incubation with KAN0439834 (S4A and S4B Fig), but inhibition of ROR1 phosphorylation as well as LRP6 was observed (Fig 8A).

Discussion

Pancreatic carcinoma is characterized by mutations and/or silencing of tumor suppressor genes, as TP53 and Smad4, mutation of KRAS and overexpression of receptor tyrosine kinases (RTKs) such as EFGR, VEGFR, IGF-IR, and RON. In addition, ROR1 was shown to be expressed in pancreatic cancer with no expression in normal pancreatic tissues [8].

Table 1. EC50 values (nM) for KAN0439834, erlotinib and ibrutinib in three pancreatic cancer cell lines.

| Cell line | KAN0439834 EC50 (nM) | Erlotinib EC50 (nM) | Ibrutinib EC50 (nM) |
|-----------|----------------------|---------------------|---------------------|
| PaCa-2    | 250                  | > 5000              | > 10000             |
| BxPC-3    | 500                  | > 5000              | > 15000             |
| Capan-1   | 650                  | > 10000             | > 15000             |

Fig 5. Cytotoxicity (%) (mean±SEM) of three pancreatic cell lines cultured (72 h) with KAN0439834 and erlotinib alone and in combination using EC50 value concentrations for the different drugs and cell lines respectively. Statistics are shown at the top.

https://doi.org/10.1371/journal.pone.0198038.g005
ROR1 plays a key role in normal embryogenesis. It is absent in most mature tissues, but highly expressed in CLL and other hematological malignancies as well as in solid tumors as breast, ovarian, lung and pancreatic cancers [11, 20]. High level of ROR1 expression is associated with a more aggressive and poor prognosis disease [11, 21]. ROR1 regulates the expression of the genes involved in epithelial-mesenchymal transition as well as sustains a favorable survival balance between the pro-survival PI3K-AKT and the pro-apoptotic p38 signaling in lung cancer [22, 23]. Knockdown of ROR1 induced apoptosis of tumor cells [12, 24]. Wnt5a, a ligand for ROR1 and ROR2, induced ROR1/ROR2 hetero-oligomerization and enhanced leukemia chemotaxis and proliferation [25]. Binding of Wnt5a to ROR1 promoted cancer cell survival and metastasis [10]. ROR1 may dimerize with the co-receptor LRP6 upon ligand activation transmitting downstream signals by SRC and the Wnt-canonical and non-canonical pathways [26].

A first-in-class small molecule KAN0439834, active against ROR1 was selected as a lead candidate following an extensive drug development process including an HTS campaign against a recombinant intracellular part of ROR1 and subsequent optimization by phenotypic screening using CLL cells. Here, the antitumor activity of KAN0439834 was explored in vitro using a panel of eight human pancreatic carcinoma cell lines expressing the phosphorylated full-length ROR1 and EGFR.

Fig 6. Cytotoxicity (%) (mean±SEM) of three pancreatic cell lines cultured (72 h) with KAN0439834 and ibrutinib alone and in combination using EC_{50} value concentrations for the different drugs and cell lines respectively. Statistics are shown at the top. 

https://doi.org/10.1371/journal.pone.0198038.g006
The main finding was that KAN0439834 had a higher killing efficacy than gemcitabine, erlotinib, ibrutinib and an anti-ROR1 mAb respectively as single agents. Additive cytotoxic effects were seen by gemcitabine, erlotinib and ibrutinib. The higher cytotoxic effects of KAN0439834 compared to anti-ROR1 mAb might be due to off-target effects of the small molecule as binding to other kinases at high concentrations (10 μM) could be noted [16]. Furthermore, complete blocking of ROR1 mediated signaling (dephosphorylation of the TK domain) could not be achieved by the mAb which was the case for the small molecule. In addition to inhibition of ROR1, LRP6 and SRC phosphorylation, KAN0439834 also inhibited phosphorylation of the PI3K/AKT/mTOR pathway, which is important in tumorigenesis [27].

The combination of KAN0439834 and anti-ROR1 mAb, two drugs targeting different structures of the ROR1 molecules, enhanced cytotoxicity in about 25% of the tested cell lines. This is in line with reports showing that the combination of anti-HER2 mAb and lapatinib might increase the apoptotic effects of HER2 expressing breast cancer cells as compared to either drug alone but not consistently [28, 29].
Previous studies using flow cytometry have shown two distinct clones of the PaCa-2 cell line [30]. As expected, the anti-ROR1 mAb induced apoptosis of the surface ROR1+ PaCa-2 cells but not of surface ROR1- cells, while KAN0439834 induced apoptosis of both fractions. ROR1 has multiple N-glycosylation sites that generate post-translationally modified ROR1 regulating ROR1 localization. The N-glycosylation sites are necessary for trafficking of ROR1 to the membrane and the function of ROR1 [31]. It is possible that differences in glycosylation and trafficking of ROR1 might affect the surface expression of ROR1 in cancer cells.

Gemcitabine has been shown to possess different cytotoxic capability in pancreatic cell lines. PaCa-2 cells were the most sensitive, Capan-1 the most resistant, and BxPC-3 cells had an intermediate sensitivity [32, 33], a similar profile as for KAN0439834. In all tested cell lines, KAN0439834 induced a higher cytotoxicity than gemcitabine. Cell lines expressing the wild-type KRAS have been shown to be more sensitive to erlotinib (EGFR inhibitor) than those with mutated KRAS [34]. However, KAN0439834 was equally effective in inducing apoptosis of pancreatic cancer cell lines irrespective of KRAS mutation.

Erlotinib and ibrutinib have been shown to induce cell death of lung and pancreatic cancer cell lines expressing members of the EGFR receptor family [35, 36]. Both drugs dephosphorylated EGFR [35]. The killing efficacy of these two drugs and KAN0439834 was compared using suboptimal concentrations (EC_{30} values). Erlotinib and ibrutinib had a similar killing capacity as KAN0439834 at EC_{30} and a clear additive effect when they were combined with KAN0439834. KAN0439834 inhibited phosphorylation of ROR1 but not EGFR and BTK, while erlotinib and ibrutinib dephosphorylated EGFR [35, 36] but not ROR1 [16] suggesting different mechanisms of action. The additive effect of KAN0439834, erlotinib and ibrutinib might partly be explained by that all three compounds cross-talk with the EGFR pathway [17].
and furthermore, both KAN0439834 and ibrutinib are inhibitors of Wnt pathways [11, 36].

EGFR may heterodimerize with HER2 activating the tyrosine kinase domain of EGFR [37]. Erlotinib had no effect on heterodimerization of EGFR and HER2 in breast cancer cells but the complex proteins (EGFR and HER2) were dephosphorylated [38]. Similarly, KAN0439834 did not affect the ROR1 and LRP6 complex (heterodimerization) but inhibited phosphorylation of the complex components.

KAN0439834 inhibited phosphorylation of ROR1, LRP6 and SRC as well as molecules of the non-canonical pathway which preceded apoptosis similar to what have been reported in CLL cells [26, 39]. SRC proteins binding to the cytoplasmic part of RTKs have been shown to be activated in lung, breast and pancreatic carcinoma cells [40]. ROR1 phosphorylation leads to interaction with and phosphorylation of SRC which is suggested to be an important step in tumorigenesis [23]. KAN0439834 also downregulated the PI3K/AKT/mTOR pathway. Activated ROR1 has been shown to trigger AKT in lung adenocarcinoma cells and ROR1 knockdown induced dephosphorylation of AKT and apoptosis. Moreover, ROR1 has been shown to utilize kinase dependent and independent mechanisms to sustain a favorable balance between PI3K/AKT pro-survival signals and the pro-apoptotic p38 pathway [23]. A significant association between the expression of ROR1 and activated AKT/CREB enhancing tumor cell growth has also been reported [14]. Up-regulation of the PI3K/AKT pathway correlated with an impaired gemcitabine-induced apoptosis in pancreatic cancer cells [41]. All these signaling molecules were downregulated by KAN0439834 which might contribute to tumor cell induced apoptosis.

In summary, a first-in-class small molecule active against phosphorylated ROR1, KAN0439834, was studied for killing capacity of pancreatic carcinoma cell lines. Tumor cell induced apoptosis by KAN0439834 was enhanced by erlotinib and ibrutinib as well as by gemcitabine. The findings are of potential therapeutic interest as the three targeting agents have different but complementary mechanisms of action in inducing tumor cell death and ibrutinib additionally also on the tumor microenvironment [42]. Further studies are warranted of this novel therapeutic principle in pancreatic carcinoma as well as in other ROR1 expressing tumors alone and specifically in combination with other targeting drugs or standard of care.

Supporting information

S1 Fig. Time-kinetics for cytotoxicity (MTT) (mean±SEM) of the PaCa-2 cell line incubated with KAN0439834 and anti-ROR1 mAb in vitro.

(DOC)

S2 Fig. Correlation between apoptosis (Annexin V/PI) and cytotoxicity (MTT) of the different pancreatic cell lines incubated with KAN0439834 for 72 h (r = 0.9182; p < 0.0001; n = 25).

(DOC)

S3 Fig. Cytotoxicity (MTT) (mean±SEM) of KAN0439834, anti-ROR1 mAb and gemcitabine alone and in combinations. (A) CFPAC-1 cell line (KAN0439834 vs gemcitabine, p = 0.0029, KAN0439834 plus gemcitabine vs KAN0439834, p = 0.0033, KAN0439834 plus gemcitabine vs gemcitabine, p = 0.0001). (B) Capan-2 cell line (KAN0439834 vs gemcitabine, p = 0.0018, KAN0439834 plus gemcitabine vs KAN0439834, p = 0.0030, KAN0439834 plus gemcitabine vs gemcitabine, p = 0.0002). (C) HPAF-II cell line (KAN0439834 vs gemcitabine, p = 0.005, KAN0439834 plus gemcitabine vs KAN0439834, p = 0.0285, KAN0439834 plus gemcitabine vs gemcitabine, p = 0.0003). (D) PaCa-44 cell line (KAN0439834 vs gemcitabine,
p = 0.0004, KAN0439834 plus gemcitabine vs KAN0439834, p = 0.0059, KAN0439834 plus gemcitabine vs gemcitabine, p = 0.0001).

S4 Fig. Heterodimerization of ROR1 and LRP6 shown by proximity ligation assay (PLA). (A) In situ PLA showing co-localization of ROR1 with LRP6 molecules in untreated PaCa-2 cells (63 X). Each red spot represents a close proximity of ROR1 and LRP6 molecules inside or on the surface of PaCa-2 cells. (B) In situ PLA assay showing co-localization of ROR1 with LRP6 molecules in PaCa-2 cells (63 X) after treatment with KAN0439834 (1 μM) (4 h). Each red spot represents a close proximity of ROR1 and LRP6 molecules inside or on the surface of PaCa-2 cells.

S1 Table. Characteristics of the human pancreatic cancer cell lines.

Acknowledgments
For expert technical assistance, we thank Ann Svensson, Kia Heimersson, Barbro Näsman, Fariba Mozaffari and for excellent secretarial assistance we thank Leila Relander and Gunilla Bureén.

Author Contributions
Conceptualization: Anders Österborg, Håkan Mellstedt.
Data curation: Amir Hossein Daneshmanesh.
Formal analysis: Amir Hossein Daneshmanesh, Håkan Mellstedt.
Funding acquisition: Lotta Hansson, Anders Österborg, Håkan Mellstedt.
Methodology: Amir Hossein Daneshmanesh, Mohammad Hojjat-Farsangi, Amineh Ghaderi, Håkan Mellstedt.
Project administration: Anders Österborg, Håkan Mellstedt.
Resources: Anders Österborg, Håkan Mellstedt.
Supervision: Anders Österborg, Håkan Mellstedt.
Validation: Amir Hossein Daneshmanesh.
Writing – original draft: Amir Hossein Daneshmanesh, Anders Österborg, Håkan Mellstedt.
Writing – review & editing: Amir Hossein Daneshmanesh, Mohammad Hojjat-Farsangi, Amineh Ghaderi, Ali Moshfegh, Lotta Hansson, Johan Schultz, Jan Vågberg, Styrbjörn Byström, Elisabeth Olsson, Thomas Olin, Anders Österborg, Håkan Mellstedt.

References
1. Malvezzi M, Bertuccio P, Levi F, La Vecchia C, Negri E. European cancer mortality predictions for the year 2013. Ann Oncol. 2013; 24(3):792–800. https://doi.org/10.1093/annonc/mdt010 PMID: 23402763.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015; 65(1):5–29. https://doi.org/10.3322/caac.21254 PMID: 25559415.
3. Spadi R, Brusa F, Ponzetti A, Chiappino I, Birocco N, Ciuffreda L, et al. Current therapeutic strategies for advanced pancreatic cancer: A review for clinicians. World J Clin Oncol. 2016; 7(1):27–43. https://doi.org/10.5306/wjco.v7.i1.27 PMID: 26862489; PubMed Central PMCID: PMCPMC4734936.
4. Taieb J, Pointet AL, Van Laethem JL, Laquente B, Pernot S, Lordick F, et al. What treatment in 2017 for inoperable pancreatic cancers? Ann Oncol. 2017; 28(7):1473–83. https://doi.org/10.1093/annonc/mdx174 PMID: 28459988.

5. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646–74. https://doi.org/10.1016/j.cell.2011.02.013 PMID: 21376230.

6. Bose P, Gandhi VV, Keating MJ. Pharmacokinetic and pharmacodynamic evaluation of irinotecan for the treatment of chronic lymphocytic leukemia: rationale for lower doses. Expert Opin Drug Metab Toxicol. 2016;1–12. https://doi.org/10.1080/17425555.2016.1239717 PMID: 27686109; PubMed Central PMCID: PMCPMC5391303.

7. Green JL, Kuntz SG, Sternberg PW. ROR receptor tyrosine kinases: orphans no more. Trends Cell Biol. 2008; 18(11):536–44. https://doi.org/10.1016/j.tcb.2008.08.006 PMID: 18848778; PubMed Central PMCID: PMCPMC4672995.

8. Balakrishnan A, Goodpaster T, Randolph-Habecker J, Hofstroom BG, Jallikis FG, Koch LK, et al. Analysis of ROR1 protein expression in human cancer and normal tissues. Clin Cancer Res. 2016. Epub 2016/11/18. https://doi.org/10.1158/1078-0432.CCR-16-2083 PMID: 27852699.

9. Borcherding N, Kusner D, Liu GH, Zhang W. ROR1, an embryonic protein with an emerging role in cancer biology. Protein Cell. 2014; 5(7):496–502. https://doi.org/10.1007/s13238-014-0059-7 PMID: 24752542; PubMed Central PMCID: PMCPMC4085287.

10. Fukuda T, Chen L, Endo T, Tang L, Lu D, Castro JE, et al. Antiserum induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a. Proc Natl Acad Sci U S A. 2008; 105(8):3047–52. https://doi.org/10.1073/pnas.0712148105 PMID: 18287027; PubMed Central PMCID: PMCPMC2268582.

11. Hojjat-Farsangi M, Moshfegh A, Daneshmanesh AH, Khan AS, Mikaelsson E, Osterborg A, et al. The receptor tyrosine kinase ROR1—an oncofetal antigen for targeted cancer therapy. Semin Cancer Biol. 2014; 29:21–31. Epub 2014/07/30. https://doi.org/10.1016/j.semcancer.2014.07.005 PMID: 25068995.

12. Choudhury A, Derkow K, Daneshmanesh AH, Mikaelsson E, Kiai S, Kokhaei P, et al. Silencing of ROR1 and FMOD with siRNA results in apoptosis of CLL cells. Br J Haematol. 2010; 151(4):327–35. https://doi.org/10.1111/j.1365-2141.2010.08362.x PMID: 20813009.

13. Daneshmanesh AH, Mikaelsson E, Jeddi-Tehrani M, Bayat AA, Ghods R, Ostadkarampour M, et al. Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy. Int J Cancer. 2008; 123(5):1190–5. Epub 2008/07/24. https://doi.org/10.1002/ijc.23587 PMID: 18546292.

14. Zhang S, Chen L, Wang-Rodriguez J, Zhang L, Cui B, Frankel W, et al. The onco-embryonic antigen ROR1 is expressed by a variety of human cancers. Am J Pathol. 2012; 181(6):1903–10. Epub 2012/10/09. https://doi.org/10.1016/j.ajpath.2012.08.024 PMID: 23041612; PubMed Central PMCID: PMC3509760.

15. Daneshmanesh AH, Hojjat-Farsangi M, Khan AS, Jeddi-Tehrani M, Akhondi MM, Bayat AA, et al. Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells. Leukemia. 2012; 26(6):1348–55. https://doi.org/10.1038/leu.2011.362 PMID: 22289919.

16. Hojjat-Farsangi M, Daneshmanesh A, Khan A, Shetye J, Mozaffari F, Kharrazah P, et al. First-in-class oral small molecule inhibitor of the tyrosine kinase ROR1 (KAN0439834) induced significant apoptosis of chronic lymphocytic leukemia cells. Leukemia. 2018.1–6. https://doi.org/10.1038/leu.2017.301 Epub 2018/03/27.

17. Lee JK, Lee J, Kim S, Kim S, Youk J, Park S, et al. Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas. J Clin Oncol. 2017:JCO2016719096. https://doi.org/10.1200/JCO.2016.71.9096 PMID: 28498782.

18. Tomizawa M, Shiozaki F, Sugiyama T, Yamamoto S, Sueishi M, Yoshida T. Insulin-like growth factor-I receptor in proliferation and motility of pancreatic cancer. World J Gastroenterol. 2010; 16(15):1854–8. https://doi.org/10.3748/wjg.v16.i15.1854 PMID: 20397262; PubMed Central PMCID: PMC2856825.

19. Yamazaki K, Friess H, Krönik MS, Buchler M, Beger HG, Korc M. Coexpression of epithelial growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res. 1993; 13(3):565–9. PMID: 8317885.

20. Daneshmanesh AH, Porwit A, Hojjat-Farsangi M, Jeddi-Tehrani M, Tamm KP, Grander D, et al. Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies. Leuk Lymphoma. 2013; 54(4):843–50. Epub 2012/09/20. https://doi.org/10.3109/10428194.2012.731599 PMID: 22988987.

21. Zheng YZ, Ma R, Zhou JK, Guo CL, Wang YS, Li ZG, et al. ROR1 is a novel prognostic biomarker in patients with lung adenocarcinoma. Sci Rep. 2016; 6:36447. https://doi.org/10.1038/srep36447 PMID: 27830754; PubMed Central PMCID: PMCPMC5103212.
22. Cui B, Zhang S, Chen L, Yu J, Widhopf GF 2nd, Fecteau JF, et al. Targeting ROR1 inhibits epithelial-mesenchymal transition and metastasis. Cancer Res. 2013; 73(12):3649–60. Epub 2013/06/19. https://doi.org/10.1158/0008-5472.CAN-12-3832 PMID: 23771907; PubMed Central PMCID: PMC3832210.

23. Yamaguchi T, Yanagisawa K, Sugiyama R, Hosono Y, Shimada Y, Arima C, et al. NKX2-1/ITF1/ITF1-1-Induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma. Cancer Cell. 2012; 21(3):348–61. https://doi.org/10.1016/j.ccr.2012.02.008 PMID: 22439932.

24. Liu Y, Yang H, Chen T, Luo Y, Xu Z, Li Y, et al. Silencing of Receptor Tyrosine Kinase ROR1 Inhibits Tumor-Cell Proliferation via PI3K/AKT/mTOR Signaling Pathway in Lung Adenocarcinoma. PLoS One. 2015; 10(5):e0127092. Epub 2015/05/16. https://doi.org/10.1371/journal.pone.0127092 PMID: 25978653; PubMed Central PMCID: PMC4433279.

25. Yu J, Chen L, Cui B, Widhopf GF 2nd, Shen Z, Wu R, et al. Wnt5a induces ROR1/ROR 2 heterooligomerization to enhance leukemia chemotaxis and proliferation. J Clin Invest. 2016; 126(2):585–98. Epub 2015/12/23. https://doi.org/10.1172/JCI83535 PMID: 26690702; PubMed Central PMCID: PMC4731190.

26. Hojjat-Farsangi M, Moshfegh A, Daneshmand AH, Vångberg J, Styrbjörn B, Vångberg J, et al. First-in-Class ROR1 Small Molecule Inhibitor (KAN0439834) Downregulated Wnt-Canonical and Non-Canonical Signaling Pathways and Induced Apoptosis of CLL Cells. Blood (American Society of Hematology 57th Annual Meeting (ASH), Abstract 2912). 2015 126(23).

27. Arcaro A, Guerreiro AS. The phosphoinositide 3-kinase pathway in human cancer: genetic alterations and therapeutic implications. Curr Genomics. 2007; 8(5):271–306. Epub 2007/08/01. https://doi.org/10.2174/138920207782446160 PMID: 19384426; PubMed Central PMCID: PMC2652403.

28. Advani P, Cornell L, Chumsri S, Moreno-Aspitia A. Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer. Breast Cancer (Dove Med Press). 2015; 7:321–35. Epub 2015/10/10. https://doi.org/10.2147/BCTT.S90627 PMID: 26451122; PubMed Central PMCID: PMC4590321.

29. Chung A, Cui X, Audeh W, Giuliano A. Current status of anti-human epidermal growth factor receptor 2 therapies: predicting and overcoming herceptin resistance. Clin Breast Cancer. 2013; 13(4):223–32. Epub 2013/07/09. https://doi.org/10.1016/j.clbc.2013.04.001 PMID: 23829888; PubMed Central PMCID: PMC3896214.

30. Gradiz R, Silva HC, Carvalho L, Botelho MF, Mota-Pinto A. MIA PaCa-2 and PANC-1—pancreas ductal adenocarcinoma cell lines with neuroendocrine differentiation and somatostatin receptors. Sci Rep. 2016; 6:21648. Epub 2016/02/18. https://doi.org/10.1038/srep21648 PMID: 26884312; PubMed Central PMCID: PMC4756684.

31. Kaucka M, Krejci P, Plevova K, Pavlova S, Prochazkova J, Janovska P, et al. Post-translational modifications regulate signalling by Ror1. Acta Physiol (Oxf). 2011; 203(3):351–62. https://doi.org/10.1111/j.1748-1716.2011.02306.x PMID: 21481194.

32. Avan A, Quint K, Nicolini F, Funel N, Frampton AE, Maftouh M, et al. Enhancement of the antiproliferative activity of gemcitabine by modulation of c-Met pathway in pancreatic cancer. Curr Pharm Des. 2013; 19(5):940–50. Epub 2012/09/15. PMID: 22973962.

33. Fryer RA, Barlett B, Galustian C, Dalgleish AG. Mechanisms underlying gemcitabine resistance in pancreatic cancer and sensitisation by the iMiD lenalidomide. Anticancer Res. 2011; 31(11):3747–56. Epub 2011/11/24. PMID: 22110196.

34. Furugaki K, Iwai T, Kondoh K, Moriya Y, Mori K. Antitumor activity of erlotinib in combination with gemcitabine in vitro and in vivo models of KRAS-mutated pancreatic cancers. Oncol Lett. 2010; 1(2):231–5. Epub 2010/03/01. https://doi.org/10.3892/ol_00000041 PMID: 22966286; PubMed Central PMCID: PMC3434647.

35. Gao W, Wang M, Wang L, Lu H, Wu S, Dai B, et al. Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells. J Natl Cancer Inst. 2014; 106(9). https://doi.org/10.1093/jnci/dju204 PMID: 25214559; PubMed Central PMCID: PMCPMC4200057.

36. Rauf F, Festa F, Park JG, Magee M, Eaton S, Rinaldi C, et al. Ibrutinib inhibition of ERBB4 reduces cell growth in a WNT5A-dependent manner. Oncogene. 2018. https://doi.org/10.1038/s41388-017-0079-x PMID: 29398709.

37. Yardimci N, Siwka M. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001; 2(2):127–37. https://doi.org/10.1038/35052073 PMID: 11252954.

38. DeFazio-Eli L, Strommen K, Dao-Pick T, Parry G, Goodman L, Winslow J. Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action. Breast Cancer Res. 2011; 13(2):R44. https://doi.org/10.1186/bcr2866 PMID: 21496232; PubMed Central PMCID: PMCPMC3219207.
39. Daneshmanesh AH, Hojjat-Farsangi M, Moshfegh A, Khan AS, Mikaelsson E, Osterborg A, et al. The PI3K/AKT/mTOR pathway is involved in direct apoptosis of CLL cells induced by ROR1 monoclonal antibodies. Br J Haematol. 2015; 169(3):455–8. https://doi.org/10.1111/bjh.13228 PMID: 25407287.

40. Wheeler DL, Iida M, Dunn EF. The role of Src in solid tumors. Oncologist. 2009; 14(7):667–78. Epub 2009/07/08. https://doi.org/10.1634/theoncologist.2009-0009 PMID: 19581523; PubMed Central PMCID: PMC3303596.

41. Ng SSW, Tsao MS, Chow S, Hedley DW. Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res. 2000; 60(19):5451–5. Epub 2000/10/18. PMID: 11034087.

42. Masso-Valles D, Jauset T, Serrano E, Sodir NM, Pedersen K, Affara NI, et al. Ibrutinib exerts potent antifibrotic and antitumor activities in mouse models of pancreatic adenocarcinoma. Cancer Res. 2015; 75(8):1675–81. https://doi.org/10.1158/0008-5472.CAN-14-2852 PMID: 25878147.